What sector does Corcept Therapeutics Incorporated belong to?

Corcept Therapeutics Incorporated operates in the Health Care sector, specifically the Pharmaceuticals industry, and is listed on the US markets.

What is the current share price of CORT?

As of the latest available quote, CORT traded at $112.79. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of CORT?

Corcept Therapeutics Incorporated has a price-to-earnings (P/E) ratio of about 250.64. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of CORT?

The market capitalisation of Corcept Therapeutics Incorporated is approximately $13.71B.

Is Corcept Therapeutics Incorporated profitable?

For its latest reported financial year, Corcept Therapeutics Incorporated recorded a net profit margin of about 13.09%.

Does CORT pay a dividend?

Corcept Therapeutics Incorporated does not currently show a dividend yield in our data.

What is the return on equity (ROE) of CORT?

Corcept Therapeutics Incorporated has a return on equity (ROE) of about 14.12%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of CORT?

Over the past 52 weeks, CORT has traded between a low of $28.66 and a high of $126.38.

Corcept Therapeutics Incorporated

CORT US Health Care Pharmaceuticals

S&P 600

$112.79

-1.85%

Delayed · cached 15 min

Fair value analysis

CORT

Corcept Therapeutics Incorporated

$112.79

Close used for this calculation

$15.62Fair value

The valuation models disagreed widely for this stock, so this figure is an unweighted average of the middle of their range. Treat it as indicative only.

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

50/100

Profitability21/25

Returns5/25

Balance Sheet18/25

Efficiency6/25

Growth12/25

Good

Quality radar

Consensus fair value

$15.62

Above FV

▼ -86.2% against the close used

Model range $6.81 – $24.60

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$6.81Fair value$15.62Bull$24.60

FairClose

52-week traded range

52W low $32.1552W high $123.57

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Corcept Therapeutics Incorporated closed at $112.79, 622.1% above the consensus fair value of $15.62 drawn from 7 valuation models.

Financial DNA score 50/100 — Good. P/E of 137.6x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

$23.16

-79.5%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

P/E Fair Value

$16.40

-85.5%

EPS × 20x (sector P/E)

EPS=0.82, Sector P/E=20x

Peter Lynch (PEG)

$24.60

-78.2%

EPS × Growth% (PEG = 1 is fair)

EPS=0.82, g=30%

EV/EBITDA

$6.81

-94.0%

(EBITDA × 18x − Net Debt) ÷ Shares

EBITDA=45.95M

Book Value (P/B)

$12.10

-89.3%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=5.96, ROE=14.1%, g=6%, r=10%

Reverse DCF

$112.79

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 33.7% | Historical: 31.5%

Margin of Safety

$14.84

-86.8%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=19.78, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer